Markets:

Overview

News

Currencies

International

Treasuries

Insulet Corporation - Common Stock (NQ:PODD)

143.02 -5.11 (-3.45%)

Streaming Delayed Price Updated: 1:55 PM EDT, Jun 2, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Insulet Corporation - Common Stock

< Previous 1 2 3 4 5 6 7 8 9

...

21 22 Next >

These S&P500 stocks are moving in today's pre-market session ↗

July 01, 2025

Let's have a look at what is happening on the US markets before the opening bell on Tuesday. Below you can find the top S&P500 gainers and losers in today's pre-market session.

Via Chartmill

$100 Invested In This Stock 15 Years Ago Would Be Worth This Much Today ↗

June 30, 2025

Via Benzinga

10 Under-the-Radar Healthcare Stocks With Incredible Growth Potential ↗

June 28, 2025

Via The Motley Fool

Topics Artificial Intelligence

INSULET CORP (NASDAQ:PODD) – A Strong Growth Stock with Technical Breakout Potential ↗

June 24, 2025

INSULET CORP (NASDAQ:PODD) shows strong revenue growth, high profitability, and a bullish technical setup, making it a noteworthy candidate for growth investors.

Via Chartmill

Here's How Much $100 Invested In Insulet 15 Years Ago Would Be Worth Today ↗

May 28, 2025

Via Benzinga

Insulet to Share Additional Evidence Demonstrating the Impact of Omnipod® 5 on Improved Health Outcomes at the American Diabetes Association 85th Scientific Sessions

June 19, 2025

From Insulet Corporation

Via Business Wire

Q1 Rundown: DexCom (NASDAQ:DXCM) Vs Other Patient Monitoring Stocks

June 17, 2025

Looking back on patient monitoring stocks’ Q1 earnings, we examine this quarter’s best and worst performers, including DexCom (NASDAQ:DXCM) and its peers.

Via StockStory

Topics Artificial Intelligence

1 Cash-Producing Stock with Exciting Potential and 2 to Steer Clear Of

June 13, 2025

A company that generates cash isn’t automatically a winner. Some businesses stockpile cash but fail to reinvest wisely, limiting their ability to expand.

Via StockStory

Novel Diagnostic Technology Disrupting Diabetic Retinopathy Market Generating Billions in Revenue Opportunities

June 17, 2025

EQNX::TICKER_START (OTCQB:AVAI),(NASDAQ:TNDM),(NYSE:NVO),(NASDAQ:PODD),(NYSE:MDT) EQNX::TICKER_END

Via FinancialNewsMedia

Tuesday's session: gap up and gap down stock in the S&P500 index ↗

June 10, 2025

Stay updated with the S&P500 gap up and gap down stocks on Tuesday. Get a glimpse of the market's movement during today's session.

Via Chartmill

Novel Diagnostic Technology Disrupting Diabetic Retinopathy Market Generating Billions in Revenue Opportunities

June 17, 2025

From FN Media Group LLC

Via GlobeNewswire

Insulet’s Omnipod® 5 App for iPhone with Dexcom G7 Integration Now Available to all U.S. Users

June 10, 2025

From Insulet Corporation

Via Business Wire

PODD Q1 Earnings Call: Insulet Highlights New Leadership and Strong Omnipod Adoption

June 10, 2025

Insulin delivery company Insulet Corporation (NASDAQ:PODD) beat Wall Street’s revenue expectations in Q1 CY2025, with sales up 28.8% year on year to $569 million. On top of that, next quarter’s revenue...

Via StockStory

Topics Economy World Trade

$100 Invested In This Stock 15 Years Ago Would Be Worth This Much Today ↗

June 09, 2025

Via Benzinga

3 Medical Technology Stocks Outperforming in 2025

June 09, 2025

Three med-tech stocks, TransMedics, Insulet, and GRAIL, are outperforming the market and their sector while forming bullish technical patterns.

Via MarketBeat

What's going on in today's session: S&P500 movers ↗

June 06, 2025

Curious about the S&P500 stocks that are in motion on Friday? Join us as we explore the top movers within the S&P500 index during today's session.

Via Chartmill

Friday's session: top gainers and losers in the S&P500 index ↗

June 06, 2025

Uncover the latest developments among S&P500 stocks in today's session. Stay tuned to the S&P500 index's top gainers and losers on Friday.

Via Chartmill

3 Reasons Investors Love Insulet (PODD)

June 05, 2025

While the broader market has struggled with the S&P 500 down 1.8% since December 2024, Insulet has surged ahead as its stock price has climbed by 18.9% to $318.02 per share. This was partly thanks to...

Via StockStory

Topics Stocks

Q1 Patient Monitoring Earnings: Insulet (NASDAQ:PODD) Earns Top Marks

June 04, 2025

Earnings results often indicate what direction a company will take in the months ahead. With Q1 behind us, let’s have a look at Insulet (NASDAQ:PODD) and its peers.

Via StockStory

Topics Artificial Intelligence

Goldman Sachs Bullish On Dexcom And Insulet As Diabetes Tech Surges ↗

June 02, 2025

Goldman Sachs forecasts strong growth for diabetes tech, backing Dexcom and Insulet while rating Tandem and Beta Bionics as Neutral.

Via Benzinga

INSULET CORP (NASDAQ:PODD) – A Strong Growth Stock with Technical Breakout Potential ↗

June 02, 2025

INSULET CORP (NASDAQ:PODD) shows strong growth fundamentals and a bullish technical pattern, making it a stock worth watching for investors seeking growth opportunities.

Via Chartmill

1 Surging Stock with Exciting Potential and 2 to Question

June 02, 2025

Exciting developments are taking place for the stocks in this article. They’ve all surged ahead of the broader market over the last month as catalysts such as new products and positive media coverage...

Via StockStory

Insulet to Present at the Goldman Sachs 46th Annual Global Healthcare Conference 2025

May 23, 2025

From Insulet Corporation

Via Business Wire

5 Analysts Assess Insulet: What You Need To Know ↗

May 22, 2025

Via Benzinga

INSULET CORP (NASDAQ:PODD) – A Strong Growth Stock Meeting Minervini’s Trend Template ↗

May 20, 2025

INSULET CORP (NASDAQ:PODD) meets Minervini’s Trend Template with strong technicals and high growth fundamentals, making it a candidate for momentum investors.

Via Chartmill

The End Of The Diabetes Industry? This Small Cap Could Upend The Business Models of Pharma Giants ↗

May 19, 2025

is it the end of the diabetes industry? Here's a small cap that could upend the business models of pharma giants...

Via Benzinga

Insulet Surges on Q1 Beat, Emerges as a Top S&P 500 Performer

May 14, 2025

Insulet's earnings and upgraded guidance recently propelled its stock to S&P 500 leadership, showcasing strong execution in the diabetes care market.

Via MarketBeat

Topics Stocks

1 Mid-Cap Stock to Target This Week and 2 to Avoid

May 14, 2025

Many investors pay attention to mid-cap stocks because they have established business models and expansive market opportunities. However, their paths to becoming $100 billion corporations are ripe with...

Via StockStory

$1000 Invested In Insulet 15 Years Ago Would Be Worth This Much Today ↗

May 13, 2025

Via Benzinga

Insulet Announces Publication of 2024 Sustainability Report

May 13, 2025

From Insulet Corporation

Via Business Wire

< Previous 1 2 3 4 5 6 7 8 9

...

21 22 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.